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A solid lipid nanoparticle (SLN) formulation was developed with the aim of improving the oral bioavail-
ability and the therapeutic effectiveness of glibenclamide (GLI), a poorly water-soluble drug used in the
treatment of type 2 diabetes. The SLN was prepared using different lipid components (Precirol and
Compritol) and preparation procedures. Precirol-based SLN, obtained with the emulsion of solvent evap-
oration technique gave the best results and was selected for drug loading. Addition of lecithin to the SLN
core or PEG coating was effective in increasing the nanoparticles stability in simulated gastric solution.
Both such formulations were stable after one month storage at 5 ± 3 C, exhibited the absence of
in vitro cytotoxicity, and presented a similar in vitro prolonged-release, reaching 100% release after
24 h. The lecithin-containing GLI-loaded SLN formulation, selected for in vivo studies in virtue of its
higher EE% than the PEG-coated formulation (70.3% vs 19.6%), showed a significantly stronger hypo-
glycemic effect with respect to the drug alone, in terms of both shorter onset time and longer duration
of the effect. These positive results indicated that the proposed SLN approach was successful in improving
GLI oral bioavailability, confirming its potential as an effective delivery system for a suitable therapy of
diabetes.
 2016 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus is one of the most common metabolic dis-
eases, and 90% of diabetic patients in the world are affected by
the non-insulin dependent Type 2 diabetes [22]. Hyperglycemia
is a serious pathologic condition that can produce a variety of seri-
ous complications over a period of years, including neurological
and cardiovascular damages. Sulfonylureas, the first widely used
oral anti-hyperglycemic drugs, act as insulin secretagogues and
trigger insulin release by inhibition of the ATP-sensitive potassium
channels of the pancreatic beta-cells [14].
Glibenclamide (or glyburide), a second-generation sulfonylurea,
is one of the most prescribed oral anti-hyperglycemic agents
[21,13]. Due to its very poor water solubility and good permeabil-
ity properties, GLI is classified as a BCS class II drug [55]. The very
poor water-solubility of the drug is responsible for its limited and
variable oral bioavailability [34], as well as for problems of non-
bio-equivalence among its different commercial tablets [6].Therefore, various approaches have been applied over the last
years aimed at improving the solubility and dissolution properties
of glibenclamide, including formation of binary [52,53] or ternary
[11] solid dispersions in hydrophilic polymers, complexation with
cyclodextrins [18,10], combined use of cyclodextrins and polymers
[61,12], formulation as liquid SMEDDS [3] or solid SMEDDS [33], or
even as microparticles [35] or nanoparticles [58,47].
However, despite the efforts thus far, no completely satisfactory
results have been still obtained and no glibenclamide products
arising from these approaches are available in the market.
In recent years, the application of nanotechnology combined
with the use of lipid-based formulations is receiving increasing
interest as a promising strategy in drug delivery to enhance the
oral bioavailability of hydrophobic drugs. As recently reviewed,
these systems are able to increase the absorption of lipophilic
drugs through the gastrointestinal tract by different mechanisms:
(a) accelerating their dissolution process, facilitating the formation
of solubilized phases, by particle size reduction to molecular level,
thus yielding a solid-state solution within the carrier; (b) changing
drug uptake, efflux and disposition, by altering the enterocyte-
based transport; and (c) enhancing the drug transport to the
systemic circulation via the intestinal lymphatic system [23]. In
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interesting and effective alternative to other particulate delivery
systems such as nanoemulsions, micelles, liposomes, and poly-
meric nanoparticles [16,30]. It has been claimed that SLN should
overcome some of the major disadvantages of other colloidal carri-
ers, such as in particular the low stability and possible biotoxicity
[31,30], and offer several advantages such as high drug loading,
protection from degradation and release modulation [1,50,9,30].
Many studies showed that SLN is actually able to prolong and/or
control drug delivery, enhance its stability and improve its
bioavailability [27,49,60,38,19]. In particular, the SLN effectiveness
in improving the oral bioavailability of poorly-soluble drugs is
mainly attributed to the nanoscale dimensions of the particles
combined with the almost molecular dispersion of the drug mole-
cules into the lipid carrier and the presence of surfactants, which
strongly increases the drug gastrointestinal solubilization, and
the in vivo absorption [15,40,54].
However, in the development of SLN formulations, it has to be
considered that many factors can affect their properties and
the performance of the final product, such as the preparation
method, the operative conditions, the nature of the materials used
[16,30].
Based on all these premises, the aim of present work was the
development of glibenclamide-loaded SLN able to improve its
therapeutic efficacy and overcome the problems of poor and
variable bioavailability. Different lipid components were examined
and different preparation procedures were used for SLN produc-
tion. The obtained formulations were characterized in terms of
drug loading, particle size and zeta-potential, and solid-state prop-
erties. Stability and cytotoxicity studies were also performed on
selected formulations. Finally, the best formulation was chosen
for in vivo studies on diabetic rats, to evaluate its therapeutic
efficacy in reducing the blood glucose levels.2. Materials and methods
2.1. Materials
Glibenclamide (GLI) was a generous gift of Menarini (Italy).
Glyceryl behenate (Compritol 888 ATO; COM) and glyceryl palmi-
tostearate (Precirol ATO5;PRE) were kindly provided by Gatte-
fossé (Saint-Priest, Cedex, France); sodium deoxycholate (SDC),
stearylamine (SA), polysorbate 20 (Tween 20), sodium dodecyl sul-
fate (SDS) and polyethylene glycol (average Mw 6000; PEG 6000)
were obtained from Sigma–Aldrich. Soya lecithin (Lipoid S100)
was a kind gift from Lipoid (Ludwigshafen, Germany). Purified
water was obtained by reverse osmosis (Elix 3 Millipore, MD,
USA). All other chemicals were at least of reagent grade and used
as received.2.2. Preparation of SLN
SLN was prepared using either the emulsification–solvent evap-
oration (ESE) or the hot high-shear homogenization (HH) tech-
niques, as previously described by Gaspar et al. [20] and Lopes
et al. [27], respectively. Briefly, for the first method, the lipid
(COM or PRE, 50 mg), alone or mixed with SA (10 mg) was
dissolved in dichloromethane, and then added dropwise to the
aqueous phase containing Tween 20 (5 mg/mL) and SDC
(6 mg/mL) and sonicated (40W, 2.5 min, Branson Sonifier 250,
USA). The obtained dispersion was homogenized for 3.5 min at
10,000 rpm using a high shear homogenizer (Silverson L5M, UK).
The dispersion obtained was then kept under magnetic stirring at
200 rpm for 4 h at room temperature until dichloromethane
complete evaporation.According to the hot high-shear homogenization (HH) method,
the lipid (50 mg), with and without SA (10 mg) was heated at
about 80 C to obtain a clear solution. Afterward, purified water
containing Tween 20 (5 mg/mL) and SDC (6 mg/mL), heated to
the same temperature, was poured into the hot lipid phase and
an emulsion was obtained by stirring 5 min at 10,000 rpm with
the high shear homogenizer (Silverson L5M, UK); finally the
dispersion was cooled at 4 C. In the case of SLN incorporating
GLI, the drug was added to the lipid phase.
Concerning stabilized SLN, empty and drug-loaded nanoparti-
cles were prepared by the ESE technique, by adding lecithin to
the lipid phase and/or molten PEG 6000 (4.5% w/w) in the lipid
phase, and/or by coating SLN with PEG 6000 added (4.5% w/w) to
the aqueous phase with agitation for 4 h at room temperature.
2.3. Measurement of particle size and zeta potential of SLN
SLN mean diameter and polydispersity index (PI) were
determined by quasi-elastic laser light scattering using a Malvern
Zetasizer 1000HSA (Malvern Instruments; UK). The surface charge
(zeta potential) was determined by laser Doppler anemometry
using a Zetasizer 2000 (Malvern Instruments, UK). Samples were
diluted appropriately for the measurements.
2.4. Determination of drug entrapment efficiency (%EE)
The drug entrapment efficiency has been determined by both
direct and indirect methods.
According to the direct method, the SLN dispersions, were first
purified by size-exclusion chromatography in a PD-10 column (GE
Healthcare, Germany) to remove the not incorporated drug. Then,
500 lL of a solution of Triton X-100 (10%), NaOH (1 N) and SDS
(8%) was added to the pre-treated colloidal dispersion and kept
2 min at 80 C to disrupt SLN; the free drug was then UV assayed
at 300 nm using a microplate Reader FLUOstar Omega (BMG Lab-
tech GmbH, Germany).
Entrapment efficiency (EE%) of GLI in SLN was calculated
according to the following equation:
%EE ¼ ðWentrapped drug=W initial drugÞ  100
where Winitial drug is the drug amount initially used and Wentrapped
drug the drug amount entrapped into SLN.
According to the indirect method, the concentration of the not
incorporated drug, present in the aqueous phase of the nanoparti-
cle dispersion, was determined after separation from SLN by ultra
filtration–centrifugation (centrifugal filters Amicon Ultra-4 with
100 kDa molecular weight cut-off, Millipore, Germany). Briefly,
1 mL of GLI-loaded SLN dispersion was put into the upper chamber
of the centrifuge filter, and then centrifuged at 4500g 20 min at
4 C. The amount of free drug in the aqueous phase, collected in
the outer chamber of the centrifuge filter, was then assayed as
described above.
Entrapment efficiency (EE%) of GLI in SLN was calculated
according to the following equations:
%EE ¼ ðW initial drug W free drug=W initial drugÞ  100
where Wfree drug is the amount of free drug in the aqueous phase
after separation of SLN.
2.5. Stability studies
Stability of SLN with time was evaluated both on the disper-
sions as such, stored at 5 ± 3 C, or in the freeze-dried form. With
this aim, after preparation, SLN formulations were divided into
two aliquots of equal volume: one was frozen overnight and
freeze-dried (Christ Alfa 1–4, Osterode am Harz, Germany), while
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gastrointestinal (GI) conditions was also evaluated.
2.5.1. Stability of SLN dispersions
Empty and drug-loaded SLN dispersions were stored at 5 ± 3 C
for at least one month and checked for mean particle diameter, PI,
zeta potential and EE%.
2.5.2. Effect of freeze-drying
To evaluate the effect of freeze-drying SLN formulations were
freeze-dried with and without cryoprotectant (10% w/v sucrose
or trehalose).
2.5.3. Effect of GI conditions
To check the stability of SLN into the GI tract, and verify the
absence of possible aggregation phenomena which could modify
the particle size of the nanoparticles, and thus negatively affect
their in vivo performance, a simulated gastric solution at pH 1.2,
alone (HCl 0.1 N, S1) or with pepsin (S2), and a simulated intestinal
solution at pH 6.8 (phosphate buffer, S3) were prepared. Then,
1 mL of each SLN dispersion was diluted with 9 mL of each GI fluid
and incubated at 37 C during 4 h. Particle size, PI and zeta poten-
tial were tested every 30 min and EE% at the end of the test.
2.6. HPLC determination of glibenclamide (GLI)
The drug HPLC assay was carried out by a LaChrom Elite HPLC
apparatus (Merck Hitachi, Darmstadt, Germany) equipped with a
L-2130 pump, an autosampler unit, and a L2450 UV/visible dual
wavelength detector. A BDS C18 (4.6 mm  100 mm) Hypersil
column (Thermo Electron Co., Waltham, MA, USA) was used as
stationary phase. The mobile phase consisted of a 45:55 (v/v)
mixture of acetonitrile/pH 3.0 phosphate buffer and a constant
flow rate of 1.0 mL/min was used. The detection was carried out
at 210 nm, the injection volume was 20 lL and the column
temperature was 35 C. For these conditions, GLI is eluted at a
retention time of 7.3 min. A calibration curve in the 1–10 mg/L
concentration range was prepared. The method was validated
performing repeated analyses of decreasing analyte amounts
[17]. The limit of quantification (LOQ) and limit of detection
(LOD) were 1.012 mg/L and 0.3036 mg/L, respectively.
2.7. Differential Scanning Calorimetry (DSC)
Thermal curves of individual components and of lyophilized
SLN were recorded using a DSC Q200 (TA Instruments, DE, USA).
Accurately weighed samples (1–2 mg) were placed in Al pans,
which were hermetically sealed, and heated at 10 C/min from
20 to 200 C under nitrogen, against an empty reference pan.
2.8. Transmission electron microscopy (TEM)
The morphological characteristics of the nanoparticles were
investigated by TEM analysis. The samples were stained with
phosphotungstic acid at 2% (w/v) during 2 min, fixed on racks of
copper covered by a membrane of carbon for observation, and then
analyzed on a JEOL Microscopy (JEM 2010, Japan) at 120 kV and the
images were acquired through a Gatan OriusTM camera.
2.9. In vitro cell viability studies
The absence of cytotoxicity of the developed SLN formulations
was assessed using the Caco-2 cell line, according to the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bro-
mide) method, as previously described, with some modifications
[8]. The Caco-2 cells (colorectal adenocarcinoma human cell line,ATCC HTB-37TM) were obtained from the American Type Cell Cul-
ture Collection. Cells were seeded on a 96-well plate at a cell den-
sity of 2  105 cells/mL 24 h before the test and incubated at 37 C
and 5% CO2 in a humidified atmosphere. Cells were then incubated
with both empty and GLI-loaded (250 lg/mL) SLN in RPMI 1640
culture medium (Gibco Invitrogen, Thermo Fisher Scientific, UK).
SDS (250 lg/mL) was used as positive control, and the culture
medium as negative control. After 24 h, the nanoparticles disper-
sions (for test cells) or the culture medium (for negative control
cells) or the SDS solution (for positive control cells) were removed
and replaced with fresh medium. The cells were added (200 lL per
well) with the MTT dye solution (5 mg/mL) and incubated 3 h at
37 C. The MTT is converted, by living cells, into a dark, water
insoluble, blue formazan product. After the incubation time, the
MTT-containing medium was completely removed and the intra-
cellular formazan crystals were dissolved and extracted with
dimethylsulfoxide. After 15 min at room temperature, the absor-
bance of the extracted solution was measured at 570 nm using a
microplate reader (Infinite M200, Tecan, Austria). The relative cell
viability was determined by the following equation:
Cell viability ð% of controlÞ ¼ Abssample=Abscontrol  100
where Abssample is the value obtained for cells treated with SLN or
SDS and Abscontrol the value obtained for cells incubated with the
culture medium alone.
Each dosage was performed in triplicate, and each experiment
was repeated at least 3 times.
2.10. In vitro release studies
The release studies were performed by a reverse dialysis bag
technique [26,28]. Briefly, 1 mg of drug as SLN dispersion, was
placed in a vessel containing 250 mL of pH 7.4 buffer at 37 C
and magnetically stirred, where different dialysis sacs (Sigma
Chemical Co, St. Louis, MO, 12,000 cut-off) containing 3 mL of pH
7.4 buffer were previously placed. At time intervals, dialysis sacs
were removed and the drug concentration in solution was assayed
by HPLC as described above. Each experiment (24 h) was carried
out in triplicate and the average values ±S.D. were calculated.
2.11. In vivo studies
Clinically normal male Sprague–Dawley rats (Harlan, Varese,
Italy), weighing approximately 280–300 g at the beginning of the
experimental procedure, were used. Animals were housed in CeSAL
(Centro Stabulazione Animali da Laboratorio, University of Flor-
ence) and acclimatized at least one week before their use. Two rats
were housed per cage (size 26  41 cm); the animals were kept at
23 ± 1 C with a 12 h light/dark cycle, fed with standard laboratory
diet and tap water ad libitum. All animal manipulations were
carried out according to the European Community guidelines for
animal care (DL 116/92, Application of European Communities
Council Directive of 24/11/1986 (86/609/EEC). The ethical policy
of Florence University complies with the NIH Guide for the Care
and Use of Laboratory Animals (US National Institutes of Health,
Publication N. 85-23, revised 1996; University of Florence assur-
ance number: A5278-01). Formal approval to conduct the experi-
ments was obtained from the Animal Subjects Review Board of
Florence University. Experiments involving animals have been
reported according to ARRIVE guidelines [25]. All efforts were
made to minimize animal suffering and reduce the number of ani-
mals used.
To induce diabetes mellitus to the rats, after blood collection for
baseline glucose determination, they were subjected to a single
intravenous tail vein injection of streptozotocin (STZ, 30 mg/kg
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[57]. Age-matched control rats were injected with an equal volume
of saline. On day 4 after STZ administration, the blood glucose level
was measured (glucometer Accu-Chek Aviva, USA) and rats with
blood glucose level >200 mg/dL were considered diabetic and
selected for experimentation. The diabetic rats were then ran-
domly divided into three groups, each of six animals.
GLI, as such or formulated as SLN, at a dose of 5 mg kg1 body
weight was dispersed in water and orally administered to rats by
gavage [36]. Control animals received the vehicle alone. Blood glu-
cose levels were measured before and after (1, 2, 4, 6, 8 and 24 h)
drug administration, by collecting the blood samples from the tail
vein of the animals. Results are expressed as mean ± SEM. All data
were analyzed by ANOVA (one-way analysis of variance) followed
by a Bonferroni’s significant difference procedure, used as post hoc
comparison. Data were analyzed using the ‘‘Origin 8.1” software.
Differences were considered statistically significant when P values
were <0.05.
2.12. Statistical analysis
Each batch was produced in three independent experiments
and all the analyses were performed in triplicate. Results are
expressed (n = 3) as mean ± standard deviation (SD). Statistical
evaluation of the data was performed by ANOVA (one-way analysis
of variance) using the GraphPad Prism, version 4.0 program. Differ-
ences were considered statistically significant when P values were
<0.05.3. Results and discussion
3.1. Development of SLN formulation as carrier for glibenclamide (GLI)
3.1.1. Influence of the preparation method and of the type of lipid
components
Two different preparation procedures were used for SLN pro-
duction i.e. the emulsification–solvent evaporation (ESE) and the
Hot High-shear homogenization (HH) techniques. Moreover, the
influence of the type of lipid component type (COM or PRE), and
of the presence or not of the positively charged SA were also
investigated, while the aqueous phase was kept constant and
based on a mixture of Tween 20 (5 mg/mL) and SDC (6 mg/mL)
as co-surfactants. The obtained SLN formulations were character-
ized and compared in terms of mean particle dimensions, polydis-
persity index and zeta potential. The results of these studies,
summarized in Table 1, showed that for all the examined formula-
tions, the ESE method resulted in significantly smaller particles
(P < 0.05), and higher homogeneity of the dispersion (as proved
by the lower values of PI). However, the relative influence of the
preparation method was found to be dependent from the SLN
composition. In fact, SLN based on COM as lipid phase, aloneTable 1
Mean size, polydispersity index (PI) and zeta potential (f) of empty SLN made of
Compritol (COM) or Precirol (PRE), containing or not stearylamine (SA), prepared by
hot-homogenization (HH) and emulsification–solvent evaporation (ESE).
Batch Lipid
component
Preparation
method
Size
(nm)
PI f (mV)
SLN1a COM HH >1000 0.84 ± 0.21 44 ± 2
SLN1b COM ESE 330 ± 10 0.39 ± 0.03 38 ± 2
SLN2a COM+SA HH >1000 0.59 ± 0.07 +14 ± 1
SLN2b COM+SA ESE Not obtained
SLN3a PRE HH 222 ± 25 0.63 ± 0.17 38 ± 2
SLN3b PRE ESE 129 ± 1 0.23 ± 0.06 34 ± 3
SLN4a PRE+SA HH 186 ± 5 0.39 ± 0.04 +8 ± 1
SLN4b PRE+SA ESE 159 ± 6 0.22 ± 0.01 +11 ± 1(SLN1) or in the presence of SA (SLN2), did not give particles in
the desired submicron size and PI range with both the preparation
methods, even though those obtained with the ESE method pre-
sented a mean size significantly smaller (P > 0.05) than those
obtained with the HH method. On the contrary, SLN containing
PRE, alone (SLN3) or with SA (SLN4), gave rise to good results in
terms of mean size and PI with both methods, while confirming
the better effectiveness of the ESE method. The addition of SA
did not result in any significant reduction of the particle dimen-
sions or improvement of their homogeneity, while it caused a
marked decrease in the zeta potential, whose values, around
+10 mV, were considered not enough for allowing a good SLN sta-
bility and avoiding aggregation phenomena. Therefore, based on
such findings, SLN based on PRE alone and prepared with the ESE
technique (SLN3b) were selected to continue the study.
3.1.2. GLI incorporation
Preliminary solubility studies of GLI in PRE, performed before
proceeding to the preparation of GLI-loaded PRE-based SLN, indi-
cated that the drug solubility in the molten lipid was 2% (w/w),
which should represent the highest amount of drug incorporable
into the lipid. A series of SLN were prepared by adding increasing
drug amounts (from 0.25 up to 2 mg) to the molten lipid
(50 mg). As a confirmation of the preliminary solubility studies,
the drug entrapment efficiency increased with increasing its con-
centration up to 1 mg, reaching about 82%, and then decreased,
being exceeding the saturation solubility in the molten PRE. More-
over, a good agreement between EE% data obtained by the direct
and indirect methods has been found, thus confirming the reliabil-
ity of the obtained results. Finally, 1 mg GLI loading (SLN3bL) did
not give rise to appreciable variations of particle size, PI and sur-
face charge of SLN, as shown in Table 2.
3.2. Stability studies of SLN
3.2.1. Stability of SLN dispersions
The stability of the SLN formulations to maintain their physico-
chemical properties in terms of particle mean diameter, PI surface
charge and drug entrapment was assessed after 1 month storage at
5 ± 3 C. No significant changes (P > 0.05) were observed in mean
size, PI and zeta potential values of empty or GLI-loaded SLN
dispersions at the end of the storage period (Table 2). Also the
entrapment efficiency remained almost constant, around 80%,
under these experimental conditions.
3.2.2. Effect of freeze-drying of SLN
Lyophilization has proved to be an effective way for enhancing
the chemical and physical stability of SLN formulations over pro-
longed periods of time. However, freezing of the sample might
cause problems of possible structural and/or functional damages
of the system, and/or subsequent difficulties in sample re-
solubilization, due to particle aggregation phenomena [30].
The usefulness of addition of cryoprotectants in improving the
quality of lyophilizates has been extensively investigated, and they
proved to be able to decrease particle aggregation phenomena and
obtain an easier re-dispersion of the freeze-dried product [46,27].
Therefore, to estimate the effect of the presence and type of cry-
oprotectant, empty and GLI-loaded SLN formulations were
freeze-dried with and without sucrose or trehalose (10% w/v).
3.2.2.1. DSC study of freeze-dried SLN. Fig. 1 shows the thermal
curves of pure GLI, PRE and cryoprotectants and of empty and
drug-loaded lyophilized SLN, containing or not the cryoprotectant.
The DSC curve of GLI presented a flat profile, with a sharp
endothermal peak at 175.87 C (DHfus 107.15 J/g), typical of its
crystalline anhydrous nature. Similarly, the thermal curve of PRE
Table 2
Effect of GLI incorporation (1 mg) on mean particle size, PI, zeta potential (f) and drug entrapment (EE%), of Precirol-based SLN freshly prepared and after one month storage at
5 ± 3 C (mean ± SD, n = 3).
Day
0 30 0 30 0 30 0 30
Sample Size (nm) PI f (mV) EE (%)
SLN3b 129.1 ± 15.2 128.2 ± 7.1 0.23 ± 0.06 0.28 ± 0.07 34 ± 3 41 ± 3 / /
SLN3bL 104.1 ± 12.3 112.1 ± 13.2 0.20 ± 0.05 0.33 ± 0.08 35 ± 3 43 ± 3 81 ± 3 80 ± 5
Fig. 1. DSC curves of pure components and of freeze-dried empty or GLI-loaded SLN, in the presence or not of sucrose or trehalose as cryoprotectants.
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147.50 J/g). The melting peak of GLI disappeared in all the SLN
samples, due to its amorphization or the almost molecular disper-
sion into the lipid matrix. In fact, the absence of the melting event
of a crystalline drug in a lipid mixture is assumed as the effect of its
solubilization in the lipidic mixture and/or its amorphization
[35,43]. On the contrary, the melting peak of PRE was clearly
detectable both in empty and in GLI-loaded SLN, even though it
appeared clearly reduced in intensity, indicating a loss of crys-
tallinity with respect to the pure lipid. The reduced crystallinity
of PRE can be attributed to both the mixing of the formulation
components and the SLN preparation method [7,48].
No appreciable variations were observed in the SLN thermal
profile after drug incorporation. The same is true for the thermal
curves of SLN containing the cryoprotectant, where a further
reduction of intensity of the PRE melting peak was observed in
both empty and loaded nanoparticles. As for the effect of the type
of cryoprotectant, sucrose appeared to be more effective than tre-
halose in stabilizing the SLN structure. In fact its colyophilization
with the SLN components caused its amorphization, proved by
the disappearance of its melting peak (190.83 C), and index of
its complete and homogeneous dispersion within the lipid matrix,
and, consequently, of its good protective effect against possible re-
crystallization phenomena of the amorphous matrix. On the con-
trary, the trehalose melting peak (98.01 C) was still present both
in empty and in loaded SLN, suggesting that it is less prone to be
effectively incorporated and intimately dispersed into the lipid
matrix.
3.2.3. Stability in gastrointestinal (GI) conditions
The first barrier to cross after SLN oral administration is repre-
sented by the physicochemical environment of the GI tract, whichcan negatively affect their stability and represent an obstacle to
their absorption [44]. In particular, particle size plays a crucial role
in their GI uptake and their clearance by the reticulo-endothelial
system and it is estimated that a particle size less than 300 nm is
advisable for the intestinal transport [30]. Stability of SLN disper-
sions was studied in different simulated gastrointestinal solutions:
pH 1.2 gastric solution alone (S1) and with pepsin (S2) and pH 6.8
intestinal solution (S3). As it can be observed in Fig. 2, the behavior
of empty and GLI-loaded SLN dispersions was very similar: in acid
environment the size of empty and loaded SLN growth rapidly,
reaching a 600–700 nm mean diameter after only 10 min of expo-
sition, and then stabilized in a range between 750 and 900 nm
until the end of the test (120 min). The low pH of the gastric med-
ium was responsible for this effect, reasonably due to critical
agglomeration phenomena caused by the strong reduction of the
surface charge of the particles, with zeta potential values close to
0 mV. On the contrary, the intestinal conditions did not cause
important variations in terms of SLN size, whose range holds stable
between 200 and 300 nm during 4 h of exposition, in virtue of the
negative values of zeta potential, ranged around 35 mV.
3.2.4. Improvement of SLN stability in gastrointestinal (GI) conditions
In order to stabilize SLN dispersions in the acidic gastric
conditions and prevent as far as possible aggregation phenomena,
allowing the particles to maintain almost unchanged their nanodi-
mensions until their arrival to the basic environment of the intesti-
nal tract, some formulations changes were experimented, by
testing the effectiveness of the addition of lecithin and/or coating
with PEG 6000.
The positive influence of lecithin in improving the stability of
SLN formulations in terms of particle size and PI has been
described in the literature [41,27,29]. This amphiphilic substance
Fig. 2. Particle size and zeta-potential of SLN3b formulation empty (A) or GLI-loaded (B) after 2 h incubation in pH 1.2 simulated gastric solution alone (S1) or in the presence
of pepsin (S2), and after 4 h in pH 6.8 simulated intestinal solution (S3). See Table 1 for SLN composition.
46 L.M.D. Gonçalves et al. / European Journal of Pharmaceutics and Biopharmaceutics 102 (2016) 41–50can reduce the interfacial tension and decrease interactions
between the aqueous and organic phases, thus facilitating the dro-
plets division during homogenization [56]. Moreover, the role of
PEG coating in improving the stability of nanoparticles in digestive
fluids [51,24] and its stealth-effect on the prolongation of the col-
loidal vectors circulation [2] are well established. Therefore, differ-
ent empty stabilized SLNs were initially prepared, as indicated in
Table 3, by addition of lecithin into the lipid phase (SLN5) or by
coating with PEG6000, in the absence (SLN6) or in the presence
(SLN7) of lecithin; the possible effect of adding PEG6000 in the
SLN core, in the absence (SLN8) and in the presence (SLN9) of
lecithin, was also evaluated. The stabilized SLN formulations were
then evaluated in terms of particle size, PI and surface charge, and
compared to the empty reference formulation (SNL3b) after prepa-
ration and after 2 h incubation into the simulated gastric fluid (S1).
As can be observed in Fig. 3, the reference formulation of SLN3bL
showed a very low stability in gastric conditions, as indicated by
a marked increase in particle size, and PI and reduction of zeta
potential. These changes were also accompanied by a clear reduc-
tion of the entrapped drug amount; in fact, after 2 h in gastric con-
ditions, the drug entrapment dropped to about 20%. The betterTable 3
Composition and characteristics in terms of mean size, polydispersity index (PI) and
zeta potential (f) of stabilized SLN formulations, empty and GLI-loaded (L).
Batch Stabilizing
component
Coating Size (nm) PI f (mV)
SLN5 Lecithin – 112.2 ± 6.1 0.31 ± 0.08 45 ± 2
SLN6 – PEG 6000 183.1 ± 3.2 0.32 ± 0.03 40 ± 2
SLN7 Lecithin PEG 6000 140.2 ± 5.4 0.28 ± 0.07 42 ± 1
SLN8 PEG6000 – 120.3 ± 8.6 0.23 ± 0.04 42 ± 1
SLN9 PEG6000 +
lecithin
– 120.0 ± 6.5 0.25 ± 0.17 37 ± 2
SLN5L Lecithin – 100.2 ± 4.2 0.23 ± 0.01 40 ± 3
SLN7L Lecithin PEG 6000 105.1 ± 2.9 0.22 ± 0.01 35 ± 1results were obtained for formulations containing lecithin alone
(SLN5), or in combination with PEG coating (SLN7), which both
showed a clear stabilizing effect against the aggregation phenom-
ena observed for the reference formulation, with a variation of the
mean diameter less than 0.8% after 2 h in the simulated gastric
medium. On the contrary, both addition of PEG6000 alone in the
SLN core (SLN8), and PEG-coating in the absence of lecithin
(SLN6) were not effective in stabilizing SLN in the gastric medium.
Finally, the combined use of lecithin and PEG 6000 in the core of
the nanoparticles (SLN9) was able to significantly reduce the parti-
cle size increase in SLN in acidic medium, but gave rise to a very
poorly homogeneous dispersion, with a PI value around 0.8. There-
fore, formulations with lecithin alone (SLN5), or combined with the
PEG 6000 coating (SLN7) were selected for drug loading with 1 mg
GLI (SLN5L and SLN7L, respectively). The two stabilized GLI-loaded
SLN formulations exhibited similar mean size values around
100 nm and low PI values, not significantly different from the ref-
erence loaded formulation without lecithin and PEG 6000
(SLN3bL). Moreover, even though an increase in the mean particle
dimension of both the stabilized SLN formulations was observed
after 2 h in acidic medium, their final size did not overcome
160 lm, and a good homogeneity of the dispersions was kept, with
PI values around 0.3.
Stabilized SLN containing lecithin alone showed a good EE% of
70.3 ± 5.2, while, unexpectedly, a clearly lower EE% value
(19.6 ± 4.8) was found for those with PEG coating, despite their
similar dimensions and stability properties. The lower entrapment
efficiency of SLN7L could be attributed to the possible solubilizing
and wetting effects of PEG toward GLI [4,11], which could produce
a hydrophilic environment around the drug, thus reducing its affin-
ity for the SLN lipid core, and/or favoring some drug losing during
the SLN formation. It was also checked that the EE% values of both
these SLN formulations remained almost unchanged after 2 h in
acidic medium.
Fig. 3. Particle size (A), polydispersity index (B) and zeta-potential (C) of the
different SLN formulations before or after 2 h incubation in pH 1.2 simulated gastric
solution (S1). See Tables 1 and 3 for SLN composition.
Fig. 4. Effect on cell viability of empty SLN (SLN3b) (F1) and GLI-loaded SLN
uncoated (SLN5L, F2) or PEG-coated (SLN7L, F3) after 24 (h) and 48 h (j)
exposition. See Tables 1 and 3 for SLN composition.
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Fig. 5. Release profiles of glibenclamide from SLN5L (r) and SLN7L (j)
formulations.
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The cytotoxicity of the selected stabilized SLN formulations was
assessed on Caco-2 cells, according to the MTT assay. Fig. 4 shows
the percent of survival of Caco-2 cells at 24 and 48 h after treat-
ment with empty SLN (SLN3b, F1) and GLI-loaded SLN uncoated
(SLN5L, F2) or PEG-coated (SLN7L, F3). The results clearly proved
the absence of cytotoxicity effect for all the samples tested, with
no significant variations in% cell viability with respect to the neg-
ative control (pure culture medium), confirming that the devel-
oped SLN formulations are safe and highly biocompatible.
3.4. In vitro release studies
The formulations of SLN5L and SLN7L were selected for drug
release studies. Amounts of formulations containing 1 mg of drugwere tested by the dialysis bag method and the results are pre-
sented in Fig. 5. The dialysis of both SLN formulations showed a
typical biphasic profile, characterized by an initial rapid release
phase, where about 20% was released within the first 30 min, fol-
lowed by a second phase with a slower release rate, where about
100% release was achieved after 24 h. No significant differences
were observed between the two SLN formulations.3.5. TEM analysis
TEM photographs of selected SLN batches (Fig. 6) demonstrated
the actual formation of homogeneous nanosized round particles.
Empty SLN5 particles (Fig. 6A) showed dimensions ranged
between 100 and 200 nm, thus supporting the results of dynamic
light scattering analysis. The corresponding GLI-loaded SLN parti-
cles (SLN5L) evidenced similar results (Fig. 6B), confirming that
drug loading did not modify shape and dimensions of the solid
lipid nanoparticles.3.6. In vivo studies of anti-glycemic effect of GLI-loaded SLN
The effectiveness of the developed SLN formulation in improv-
ing the anti-glycemic effect of GLI was investigated in vivo on male
rats rendered diabetic by a single intravenous tail vein injection of
STZ, in comparison with the simple aqueous dispersion of the drug,
both orally administered by gavage (5 mg kg1 body weight). The
SLN5L formulation was selected for this study, in virtue of its
Fig. 6. TEM photographs of empty SLN (SLN5) (top) and GLI-loaded (SLN5L)
(bottom). See Table 3 for SLN composition.
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in Table 4, showed that the reduction of the blood glucose level
obtained after drug alone administration reached an acceptable
value only after 4 h and then climbed rather quickly to the initial
high levels, becoming no more significantly different from the
pre-test value after 8 h. In contrast, the administration of GLI for-
mulated as SLN not only showed a more rapid onset of the blood
glucose level reduction, which became significantly different from
the pre-test just 1 h after administration, but also remained
significantly lower than the pre-test value also after 8 h. Moreover,
the anti-glycemic effect obtained with the SLN formulation
remained significantly higher than that given by drug alone from
the first until to the eighth hour after drug administration, further
confirming the higher therapeutic effectiveness of the GLI-SLN
formulation.
Most of the previous reports about the use of different formula-
tive strategies to improve the dissolution properties of GLI
[18,53,10,61,11,12,3,58,33,47] do not provide data about the actual
consequent improvement of in vivo bioavailability and therapeutic
efficacy of the drug from such formulations. On the other hand, an
increase in GLI bioavailability has been reported for its solid
dispersions in Gelucire or PEG 6000 with respect to a commercialTable 4
Blood glucose levels of diabetic rats after oral drug administration (5 mg kg1 body weigh
Blood glucose levels (mg/dL)
Treatment Pretest 1 h 2 h
STZ + GLI 340.6 ± 24.6 322.0 ± 21.6 193.0 ± 18.0^
STZ + SLN5L 334.0 ± 12.8 261.0 ± 18.1^,§ 142.6 ± 8.9^,§
^ P < 0.05 vs pretest of the same group.
§ P < 0.05 vs STZ + GLI group.formulation (Daonil tablets (Hoechst)), but without any effect on
the duration of the antiglycemic action [52]. On the contrary, a pro-
longed effect was found from GLI solid lipid microparticles, but
accompanied by a some decrease in the intensity of the antiglyce-
mic effect with respect to the commercial formulation [35]. There-
fore, no one of the previously reported formulative approaches was
able to improve at the same time both the intensity and the dura-
tion of the drug therapeutic effect, as instead we obtained with the
GLI SLN formulation.
The significant enhancement of GLI hypoglycemic effect was
observed after its administration as SLN dispersion can be attribu-
ted to an improved drug absorption from the lipid-based carrier,
even though the mechanisms underlying this effect still remain
to be fully understood. In fact, the reasons for the improved oral
bioavailability of drugs, obtained by lipid-based delivery systems,
including SLN, as well as the question if the drugs formulated as
SLN are absorbed as free drug or in the form of SLN have not been
well clarified yet, even though different possible mechanisms have
been proposed to provide an interpretation to the absorption-
enhancing phenomenon. Among these, one of the most accepted
is that SLN can facilitate the oral absorption of poorly-water sol-
uble drugs by maintaining a solubilized state of the drugs in the
GI tract, and by facilitating the formation of mixed micelles, pro-
moting secretion of endogenous phospholipids and bile salts
[32,39]. Besides, bioadhesion of SLNs to the gut wall seems to pro-
long the residence time of SLNs in the GI tract and enhance their
intimate contact with epithelial membranes, which possibly con-
tribute to enhance oral drug absorption [32,62]. The potential
muco-penetrating ability of SLN is another aspect possibly respon-
sible for the enhanced oral drug absorption [5,59]. Also the small
particle size and the surface characteristics of the nanoparticles
have an important role [42]. An additional reason for the improved
drug absorption from SLN could be attributed to the enhancement
of lymphatic delivery: lipids can stimulate lipoprotein formation
and intestinal lymphatic lipid flux to increase the extent of lym-
phatic drug transport [37,45].
4. Conclusions
A SLN formulation has been developed aimed to overcome the
problems of poor and variable oral bioavailability of GLI and
improve its therapeutic effectiveness. Preliminary studies per-
formed on empty nanoparticles enabled selection of the best
preparation technique (emulsion solvent evaporation) and the
best lipid component (Precirol) to use for preparation of GLI-
loaded SLN with the desired nanosized dimension and high
homogeneity. Addition of lecithin to the SLN core or PEG coating
was effective in increasing the nanoparticles stability in simulated
gastric environment, avoiding aggregation phenomena. Both the
developed formulations were stable after one month storage at
5 ± 3 C, exhibited the absence of cytotoxicity, and showed similar
prolonged release profiles.
The lecithin-containing GLI-loaded SLN formulation was
selected for in vivo studies, due to its higher EE% than the PEG-
coated formulation. The results of in vivo studies evidenced the
significantly stronger hypoglycemic effect of such formulation,t) such as (GLI) or formulated as SLN (SLN5L).
4 h 6 h 8 h 24 h
120.3 ± 11.6^ 197.0 ± 11.2^ 299.9 ± 22.5 325.6 ± 20.4
95.3 ± 12.7^,§ 160.6 ± 10.3^,§ 255.6 ± 25.3^,§ 330.5 ± 18.8
L.M.D. Gonçalves et al. / European Journal of Pharmaceutics and Biopharmaceutics 102 (2016) 41–50 49with respect to the drug alone, in terms of both shorter onset time
and longer duration of the effect.
Even if more in-depth investigations will be needed to elucidate
the effective mechanisms responsible for the improved drug
absorption, these positive results indicated that the proposed SLN
approach was successful in improving GLI oral bioavailability,
showing its potential in obtaining a more effective GLI-based oral
therapy of diabetes mellitus.References
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